Page last updated: 2024-12-06

bis(4-methyl-1-homopiperazinylthiocarbonyl)disulfide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide: An inhibitor of the last step of noradrenaline biosynthesis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID33295
SCHEMBL ID1195559
MeSH IDM0008531

Synonyms (30)

Synonym
bis(4-methyl-1-homopiperazinyl thio carbonyl)-disulfide
26087-98-9
(4-methyl-1,4-diazepane-1-carbothioyl)sulfanyl 4-methyl-1,4-diazepane-1-carbodithioate
bis(4-methyl-1,4-diazepan-1-yl)dithioperoxyanhydride
brn 0561859
1h-1,4-diazepine, 1,1'-(dithiodicarbonothioyl)bis(hexahydro-4-methyl-
disulfide, bis((hexahydro-4-methyl-1h-1,4-diazepin-1-yl)thiocarbonyl)
einecs 247-450-6
bis(4-methyl-4-aza-1,1-hexamethylene)thiuram disulphide
bis((hexahydro-4-methyl-1h-1,4-diazepin-1-yl)thiocarbonyl)disulfide
fla 63
fla-63
1h-1,4-diazepine, 1,1'-(dithiodicarbonothioyl)bis(hexahydro-4-methyl)
bis(4-methyl-1-homopiperazinylthiocarbonyl)disulfide
unii-6xx8m7p9dc
6xx8m7p9dc ,
bis-(4-methyl-1-homopiperazinylthiocarbonyl)disulfide
FT-0623047
SCHEMBL1195559
bis(4-methyl-1,4-diazepan-1-yl)dithioperoxyanhydride #
1h-1,4-diazepine, 1,1'-(dithiodicarbonothioyl)bis[hexahydro-4-methyl-
NXJOFTRBTBDSHB-UHFFFAOYSA-N
bis(4-methyl-1-homopiperazinylthiocarbonyl) disulfide
DTXSID00180715
AKOS030239792
J-016248
bis-(4-methyl-1-homopiperazinylthiocarbonyl)-disulfide
4-methyl-1,4-diazepane-1-carbothioic dithioperoxyanhydride
Q27265691
1h-1,4-diazepine, 1,1'-(dithiodicarbonothioyl)bis[hexahydro-4-methyl- (9ci)

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"In Experiment 1, the dose-response effects of three dopamine-beta-hydroxylase (DBH) inhibitors (diethyldithiocarbamate, FLA-63 and U-14, 624) on the endogenous levels of norepinephrine and dopamine in pons-medulla of rat brain were determined."( Possible role of dopamine-beta-hydroxylase in the regulation of norepinephrine biosynthesis in rat brain.
Belluzzi, JD; Stein, L; Wise, CD, 1977
)
0.26
" But 3 or 5 days after prior reserpinisation, FLA-63 in the same dosage suppressed or profoundly depressed self-stimulation without eliciting signs of general incapacity."( Self-stimulation and noradrenaline: evidence that inhibition of synthesis abolishes responding only if the "reserve" pool is dispersed first.
Franklin, KB; Herberg, LJ, 1975
)
0.25
" Results of assays of norepinephrine and dopamine levels in MBH after the various treatments suggest that, at the dosage used, U-14,624 has a greater effect on norepinephrine and dopamine levels that the other dopamine-beta-hydroxylase inhibitors."( Some catecholamine inhibitors do not cause accumulation of nuclear estrogen receptors in rat hypothalamus and anterior pituitary gland.
Blaustein, JD; Brown, TJ; McElroy, JF, 1986
)
0.27
" A non-anorectic dosage of L110-140 (3."( The role of norepinephrine in feeding behavior.
Davies, RF; Panksepp, J; Rossi, J; Zolovick, AJ, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (177)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990166 (93.79)18.7374
1990's10 (5.65)18.2507
2000's1 (0.56)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.04 (24.57)
Research Supply Index5.23 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other184 (98.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]